BCL2 and gastric cancer: Isoquercitrin at concentrations of 20–80 μM significantly elevated the levels of p-PERK, p-eIF2α, GRP78 and CHOP in gastric cancer HGC-27 and AGS cells while downregulating BCL-2 expression, upregulating BAX expression and cleaved caspase-3/12, and activating the ERS pathway; moreover, isoquercitrin enhanced the level of the immunogenic cell death (ICD) markers ATP, high-mobility group Box 1 (HMGB1), HSP70 and HSP90, promoting ICD and disrupting the immunosuppression of gastric cancer cells, thereby inducing cell death (Liu et al., 2023).